MAP2K7 and neoplasm: Previous work supports an independent role of BRAF and MEK inhibitor combination therapy in increasing tumor-infiltrating lymphocyte populations and inflammatory cytokine levels, suggesting that this effect cannot be attributed solely to exposure to the anti-PD-L1 antibody, durvalumab10,14.